Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2023 08:00 ET | Source: EG 427

EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment

Issued European and Japanese patents cover herpes simplex virus (HSV) vectors selectively inhibiting subtype of sensory neuronsRelated initial therapeutic indications encompass multiple bladder...
March 27, 2023 08:00 ET | Source: EG 427

EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board

Venture and pharmaceutical industry veteran, Sundar Kodiyalam, becomes a new member on Board of Directors. Leading expert in herpes virus vector research, Gregory A. Smith, Ph.D., joins Scientific...
November 29, 2022 05:00 ET | Source: EG 427

EG 427 appoints Cornelia Haag-Molkenteller, M.D., Ph.D., as Chief Medical Officer

PARIS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company leading the development of pinpoint gene therapy solutions based on its unique non-replicative HSV-1 vector platform,...
September 14, 2021 01:00 ET | Source: EG 427

EG 427 appoints Grzegorz Sarek, Ph.D., as Vice President of Research

PARIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company leading the development of pinpoint gene therapy solutions by using a unique HSV-1 vector platform, today announced the...
March 01, 2021 08:00 ET | Source: EG 427

EG 427 announces €12 million Series A financing to advance its HSV-1 based gene therapy

David Lamond and Stephane Boissel join the company’s board of Directors PARIS, March 01, 2021 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company developing pinpoint gene therapy, today announced...

keyboard_arrow_left Previous Page